Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study-Reference-Cited by-同舟云学术

Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study

Published:2019-12-11 Issue:6 Volume:126 Page:1253-1263
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kobayashi Hiroshi¹^ORCID,Iwata Shintaro²^ORCID,Wakamatsu Toru³^ORCID,Hayakawa Keiko⁴,Yonemoto Tsukasa⁵,Wasa Junji⁶,Oka Hiroyuki⁷,Ueda Takafumi⁸,Tanaka Sakae¹

Affiliation:

1. Department of Orthopaedic Surgery The University of Tokyo Hospital Tokyo Japan

2. Division of Orthopedic Surgery National Cancer Center Hospital Tokyo Japan

3. Department of Musculoskeletal Oncology Service Osaka International Cancer Institute Osaka Japan

4. Department of Orthopedic Surgical Oncology Cancer Institute HospitalJapanese Foundation for Cancer Research Tokyo Japan

5. Division of Orthopedic Surgery Chiba Cancer Center Chiba Japan

6. Department of Orthopedic Surgery Shizuoka Cancer Center Hospital Shizuoka Japan

7. Department of Medical Research and Management for Musculoskeletal Pain, 22nd Century Medical and Research Center, Faculty of Medicine The University of Tokyo Hospital Tokyo Japan

8. Department of Orthopedic Surgery National Hospital Organization Osaka National Hospital Osaka Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32661

Reference24 articles.

1. The role of margins in extremity soft tissue sarcoma

2. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis

3. Evolving Treatment of Soft Tissue Sarcoma

4. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

5. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications;Cancer and Metastasis Reviews;2024-08-09

2. Long-term efficacy of eribulin in patients with advanced myxoid liposarcoma resistant to trabectedin: A case report;JOS Case Reports;2024-06

3. 当科における進行軟部肉腫に対するトラベクテジンの使用経験;Orthopedics & Traumatology;2024-03-25

4. Factors predictive of second‐line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database;Cancer Science;2023-12-19

5. Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies;ESMO Open;2023-10